<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>BioScreening.net &#187; Mergers and Acquisitions</title>
	<atom:link href="http://www.bioscreening.net/category/industry-trends/mergers-and-acquisitions/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.bioscreening.net</link>
	<description>BioScreening news and events</description>
	<lastBuildDate>Thu, 29 Dec 2011 08:21:20 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3</generator>
		<item>
		<title>Actelion obtains option to acquire privately-held Trophos</title>
		<link>http://www.bioscreening.net/2010/08/05/actelion-obtains-option-to-acquire-privately-held-trophos/</link>
		<comments>http://www.bioscreening.net/2010/08/05/actelion-obtains-option-to-acquire-privately-held-trophos/#comments</comments>
		<pubDate>Thu, 05 Aug 2010 18:04:08 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1016</guid>
		<description><![CDATA[Late-stage Phase III compound in Amyotrophic Lateral Sclerosis to report data in late 2011 – Novel therapeutic approach to be further explored in drug discovery collaboration ALLSCHWIL, SWITZERLAND and MARSEILLE, FRANCE – 20 July 2010 – Actelion Ltd (SIX: ATLN) and privately-held Trophos SA announced today that they have entered into a binding agreement whereby [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/08/05/actelion-obtains-option-to-acquire-privately-held-trophos/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sanofi-aventis&#8217; purchase aligned with technology &#8216;coming of age&#8217;</title>
		<link>http://www.bioscreening.net/2010/05/05/sanofi-aventis-purchase-aligned-with-technology-coming-of-age/</link>
		<comments>http://www.bioscreening.net/2010/05/05/sanofi-aventis-purchase-aligned-with-technology-coming-of-age/#comments</comments>
		<pubDate>Wed, 05 May 2010 21:16:28 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/05/05/sanofi-aventis-purchase-aligned-with-technology-coming-of-age/</guid>
		<description><![CDATA[Sanofi-aventis&#8217; acquisition of the pharmaceutical development company that began as Selectide is &#8220;coincident with the technology, essentially, coming of age,&#8221; according to Tucson Research Center scientific director Ken Wertman. &#8220;It is inextricably tied to this sense we have reached the objective;&#8221; namely, to use technology to effectively develop and analyze compounds for further investigation as [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/05/05/sanofi-aventis-purchase-aligned-with-technology-coming-of-age/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>2009: The Year That Was For Pfizer</title>
		<link>http://www.bioscreening.net/2010/01/28/2009-the-year-that-was-for-pfizer/</link>
		<comments>http://www.bioscreening.net/2010/01/28/2009-the-year-that-was-for-pfizer/#comments</comments>
		<pubDate>Thu, 28 Jan 2010 20:46:34 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/01/28/2009-the-year-that-was-for-pfizer/</guid>
		<description><![CDATA[(RTTNews) &#8211; True to expectations, Jeffrey Kindler, the CEO of Pfizer Inc. (PFE &#124; Quote &#124; Chart &#124; News &#124; PowerRating), scripted a new playbook for the drug giant in 2009, accelerating the process of transformation by clinching the largest pharmaceutical deal in nearly a decade. The acquisition of Wyeth for $68 billion earlier this [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/01/28/2009-the-year-that-was-for-pfizer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Commonwealth Biotechnologies, Inc. Acquisition of GL Biochem: Market Update</title>
		<link>http://www.bioscreening.net/2009/12/01/commonwealth-biotechnologies-inc-acquisition-of-gl-biochem-market-update/</link>
		<comments>http://www.bioscreening.net/2009/12/01/commonwealth-biotechnologies-inc-acquisition-of-gl-biochem-market-update/#comments</comments>
		<pubDate>Tue, 01 Dec 2009 15:24:37 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/12/01/commonwealth-biotechnologies-inc-acquisition-of-gl-biochem-market-update/</guid>
		<description><![CDATA[Shareholders approve sale of the Richmond, Virginia assets as required under the GL Biochem Asset Purchase Agreement RICHMOND, Va.&#8211;(Business Wire)&#8211; Commonwealth Biotechnologies, Inc. (&#8220;CBI&#8221;) (NASDAQ Capital Market: CBTE) has recently announced a definitive share purchase agreement to acquire Shanghai-based GL Biochem and associated businesses (the &#8220;GL Group&#8221;), the largest global supplier of research-grade peptide products [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/12/01/commonwealth-biotechnologies-inc-acquisition-of-gl-biochem-market-update/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Eurogentec  Announces Agreement to Acquire AnaSpec, Inc.</title>
		<link>http://www.bioscreening.net/2009/10/29/eurogentec-announces-agreement-to-acquire-anaspec-inc/</link>
		<comments>http://www.bioscreening.net/2009/10/29/eurogentec-announces-agreement-to-acquire-anaspec-inc/#comments</comments>
		<pubDate>Thu, 29 Oct 2009 14:24:37 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/10/29/eurogentec-announces-agreement-to-acquire-anaspec-inc/</guid>
		<description><![CDATA[LiÃ¨ge, Belgiumâ€”October 23, 2009. Eurogentec S.A. (â€œEurogentecâ€) announces today a final agreement for the acquisition of AnaSpec Inc (â€œAnaSpecâ€ or the â€œCompanyâ€), a privately held proteomics company based in Fremont, California. Founded in 1993, AnaSpec is a leading provider of integrated proteomics solutions for life science research and diagnostics with expertise in peptides synthesis, labeled [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/10/29/eurogentec-announces-agreement-to-acquire-anaspec-inc/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG Company gains access to proprietary antibody fragment technology particularly suited to treat eye diseases</title>
		<link>http://www.bioscreening.net/2009/10/09/alcon-to-acquire-swiss-biotechnology-firm-esbatech-ag-company-gains-access-to-proprietary-antibody-fragment-technology-particularly-suited-to-treat-eye-diseases/</link>
		<comments>http://www.bioscreening.net/2009/10/09/alcon-to-acquire-swiss-biotechnology-firm-esbatech-ag-company-gains-access-to-proprietary-antibody-fragment-technology-particularly-suited-to-treat-eye-diseases/#comments</comments>
		<pubDate>Fri, 09 Oct 2009 16:42:57 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/10/09/alcon-to-acquire-swiss-biotechnology-firm-esbatech-ag-company-gains-access-to-proprietary-antibody-fragment-technology-particularly-suited-to-treat-eye-diseases/</guid>
		<description><![CDATA[HUENENBERG, Switzerland &#038; ZURICH, Sep 13, 2009 (BUSINESS WIRE) &#8212; &#8211;Acquisition establishes sustainable platform for ongoing biologics development &#8211;Deal builds on other recent transactions to expand breadth and depth of Alcon&#8217;s development opportunities in eye care in the long term &#8211;ESBATech shareholders retain rights to non-ophthalmic technology and products Alcon /quotes/comstock/13*!acl/quotes/nls/acl (ACL 141.64, +1.02, +0.73%) [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/10/09/alcon-to-acquire-swiss-biotechnology-firm-esbatech-ag-company-gains-access-to-proprietary-antibody-fragment-technology-particularly-suited-to-treat-eye-diseases/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sigma-Aldrich buys ChemNavigator</title>
		<link>http://www.bioscreening.net/2009/08/25/sigma-aldrich-buys-chemnavigator/</link>
		<comments>http://www.bioscreening.net/2009/08/25/sigma-aldrich-buys-chemnavigator/#comments</comments>
		<pubDate>Tue, 25 Aug 2009 14:48:03 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/08/25/sigma-aldrich-buys-chemnavigator/</guid>
		<description><![CDATA[Sigma-Aldrich said Thursday that it acquired ChemNavigator.com Inc., a provider of software used to identify and procure chemistry needed for drug discovery and research, for an undisclosed sum. ChemNavigator, which has operations in San Diego and in Australia, provides chemists with virtual screening tools and products that allow them to channel their chemical designs toward [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/08/25/sigma-aldrich-buys-chemnavigator/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Forget the Shortcuts: Creating a Truly Innovative Biotech Culture</title>
		<link>http://www.bioscreening.net/2009/08/21/forget-the-shortcuts-creating-a-truly-innovative-biotech-culture/</link>
		<comments>http://www.bioscreening.net/2009/08/21/forget-the-shortcuts-creating-a-truly-innovative-biotech-culture/#comments</comments>
		<pubDate>Fri, 21 Aug 2009 19:24:29 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/08/21/forget-the-shortcuts-creating-a-truly-innovative-biotech-culture/</guid>
		<description><![CDATA[Watching the acquisition of Genentech by Roche has been a fascinating process. I wasnâ€™t so interested in the eventual price paid per share, but whether Basel, Switzerland-based Roche, one of the oldest and most traditional pharma companies, could preserve the special science-based culture at Genentech that made it the worldâ€™s pre-eminent biotech company. Would Genentechâ€™s [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/08/21/forget-the-shortcuts-creating-a-truly-innovative-biotech-culture/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Company and People Notes: Patheon and Solvias Form Alliance; AstraZeneca Appoints Rich Fante President of US Business; More&#8230;</title>
		<link>http://www.bioscreening.net/2008/11/26/company-and-people-notes-patheon-and-solvias-form-alliance-astrazeneca-appoints-rich-fante-president-of-us-business-more/</link>
		<comments>http://www.bioscreening.net/2008/11/26/company-and-people-notes-patheon-and-solvias-form-alliance-astrazeneca-appoints-rich-fante-president-of-us-business-more/#comments</comments>
		<pubDate>Wed, 26 Nov 2008 17:38:21 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Collaborations]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[Peptide Research]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2008/11/26/company-and-people-notes-patheon-and-solvias-form-alliance-astrazeneca-appoints-rich-fante-president-of-us-business-more/</guid>
		<description><![CDATA[Nov 20, 2008 ePT&#8211;the Electronic Newsletter of Pharmaceutical Technology Company Notes San Jose, CA (Nov. 14)â€”AnaSpec established a new facility dedicated to peptide production that complies with good manufacturing practice (GMP). The new facility is adjacent to AnaSpecâ€™s headquarters and provides 5000 ft2 of dedicated GMP space, including two Class 10,000 cleanrooms. AnaSpec produces GMP [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2008/11/26/company-and-people-notes-patheon-and-solvias-form-alliance-astrazeneca-appoints-rich-fante-president-of-us-business-more/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases</title>
		<link>http://www.bioscreening.net/2007/08/29/upstream-biosciences-acquires-innovative-platform-technology-and-drug-candidates-for-tropical-parasitic-diseases/</link>
		<comments>http://www.bioscreening.net/2007/08/29/upstream-biosciences-acquires-innovative-platform-technology-and-drug-candidates-for-tropical-parasitic-diseases/#comments</comments>
		<pubDate>Wed, 29 Aug 2007 17:19:53 +0000</pubDate>
		<dc:creator>Fred</dc:creator>
				<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2007/08/29/upstream-biosciences-acquires-innovative-platform-technology-and-drug-candidates-for-tropical-parasitic-diseases/</guid>
		<description><![CDATA[-Acquisition of Pacific Pharma Technologies Brings Proprietary Artificial Intelligence-Based Drug Discovery Platform and Novel Drug Candidates to Upstream&#8211;Initial Compounds Demonstrate Promising In Vitro Activity Against Devastating Parasitic Diseases Affecting 300 Million People Worldwide- VANCOUVER, B.C., Aug. 27 /PRNewswire-FirstCall/ &#8212; Upstream Biosciences Inc. today announced it has completed the acquisition of Pacific Pharma Technologies Inc., an [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2007/08/29/upstream-biosciences-acquires-innovative-platform-technology-and-drug-candidates-for-tropical-parasitic-diseases/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Michigan High Throughput Screening Center and NSF International Announce New Partnership</title>
		<link>http://www.bioscreening.net/2007/08/01/michigan-high-throughput-screening-center-and-nsf-international-announce-new-partnership/</link>
		<comments>http://www.bioscreening.net/2007/08/01/michigan-high-throughput-screening-center-and-nsf-international-announce-new-partnership/#comments</comments>
		<pubDate>Wed, 01 Aug 2007 16:13:25 +0000</pubDate>
		<dc:creator>Fred</dc:creator>
				<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2007/08/01/michigan-high-throughput-screening-center-and-nsf-international-announce-new-partnership/</guid>
		<description><![CDATA[ANN ARBOR, MI and KALAMAZOO, MI, July 31, 2007&#8211; Global Lifescience Solutions, an NSF International Company offering contract research services to the biotechnology and pharmaceutical industries, today announced a new partnership with the Michigan High Throughput Screening Center (MHTSC). MHTSC is a not-for-profit, contract research laboratory that provides assay development and state-of-the-art high throughput screening [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2007/08/01/michigan-high-throughput-screening-center-and-nsf-international-announce-new-partnership/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Preclinical services news in brief &#8211; In this week&#8217;s review of activity within the preclinical research services arena, news has emerged involving ZoBio, Charles River Laboratories and TetraQ</title>
		<link>http://www.bioscreening.net/2007/07/16/preclinical-services-news-in-brief-in-this-weeks-review-of-activity-within-the-preclinical-research-services-arena-news-has-emerged-involving-zobio-charles-river-laboratories-and-tetraq/</link>
		<comments>http://www.bioscreening.net/2007/07/16/preclinical-services-news-in-brief-in-this-weeks-review-of-activity-within-the-preclinical-research-services-arena-news-has-emerged-involving-zobio-charles-river-laboratories-and-tetraq/#comments</comments>
		<pubDate>Mon, 16 Jul 2007 19:14:51 +0000</pubDate>
		<dc:creator>Fred</dc:creator>
				<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2007/07/16/preclinical-services-news-in-brief-in-this-weeks-review-of-activity-within-the-preclinical-research-services-arena-news-has-emerged-involving-zobio-charles-river-laboratories-and-tetraq/</guid>
		<description><![CDATA[Belgian biopharma firm UCB has this week selected ZoBio to provide ligand screening services for some of its targets in the field of fragment-based drug discovery. ZoBio will undertake this task using its proprietary Target Immobilized Nuclear Magnetic Resonance (NMR) Screening (TINS) technology. According to ZoBio, TINS is capable of&#8221; rapidly generating high affinity, high [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2007/07/16/preclinical-services-news-in-brief-in-this-weeks-review-of-activity-within-the-preclinical-research-services-arena-news-has-emerged-involving-zobio-charles-river-laboratories-and-tetraq/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BioServe Acquires Genomics Collaborative</title>
		<link>http://www.bioscreening.net/2007/05/04/bioserve-acquires-genomics-collaborative/</link>
		<comments>http://www.bioscreening.net/2007/05/04/bioserve-acquires-genomics-collaborative/#comments</comments>
		<pubDate>Fri, 04 May 2007 23:20:34 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Genomics & Pharmacogenomics]]></category>
		<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2007/05/04/bioserve-acquires-genomics-collaborative/</guid>
		<description><![CDATA[BioServe Extends Genomics Services Platform with Premier Industrial Biobank for Biomarker Discovery and Validation Beltsville, MD, May 1st, 2007 â€“ BioServe, a leading provider of genomics services, today announced that it has acquired Genomics Collaborative from SeraCare Life Sciences, Inc. Genomics Collaborative is a leader in facilitating biomarker discovery and validation through its Global RepositoryÂ®, [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2007/05/04/bioserve-acquires-genomics-collaborative/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Galapagos Announces Third Quarter 2005 Results</title>
		<link>http://www.bioscreening.net/2005/11/10/galapagos-announces-third-quarter-2005-results/</link>
		<comments>http://www.bioscreening.net/2005/11/10/galapagos-announces-third-quarter-2005-results/#comments</comments>
		<pubDate>Thu, 10 Nov 2005 17:26:10 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Business and Investment]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Reagents]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2005/11/10/galapagos-announces-third-quarter-2005-results/</guid>
		<description><![CDATA[&#8212; Acquisition of BioFocus completed, integration progresses as planned &#8212; Galapagos year to date revenues 8% below last year&#8217;s revenues, but cash burn in line with forecast &#8212; Revenue guidance for 4Q &#8217;05 of 7.7 million, full year cash burn of 7 million &#8212; Strong cash position of 25 million on Sept. 30, 2005 &#8212; [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2005/11/10/galapagos-announces-third-quarter-2005-results/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Fisher acquires Oakland company</title>
		<link>http://www.bioscreening.net/2005/08/05/fisher-acquires-oakland-company/</link>
		<comments>http://www.bioscreening.net/2005/08/05/fisher-acquires-oakland-company/#comments</comments>
		<pubDate>Fri, 05 Aug 2005 17:40:23 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[North America]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2005/08/05/fisher-acquires-oakland-company/</guid>
		<description><![CDATA[Cellomics Inc., hailed as one of Pittsburgh&#8217;s most promising life science start-up companies, has been acquired by Fisher Scientific International Inc., a firm with century-old Pittsburgh roots. Hampton, N.H.-based Fisher, a maker of laboratory equipment, has been pushing aggressively into the life science arena with several acquisitions in recent years. Fisher Scientific said it will [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2005/08/05/fisher-acquires-oakland-company/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Novasite Pharmaceuticals Announces Acquisition of PsyCheNomicS, Inc.; Novasite Augments Pipeline of CNS Drug Candidates; James Hauske, Ph.D. Joins Novasite as Executive Vice President Drug Discovery</title>
		<link>http://www.bioscreening.net/2005/06/15/novasite-pharmaceuticals-announces-acquisition-of-psychenomics-inc-novasite-augments-pipeline-of-cns-drug-candidates-james-hauske-phd-joins-novasite-as-executive-vice-president-drug-discovery/</link>
		<comments>http://www.bioscreening.net/2005/06/15/novasite-pharmaceuticals-announces-acquisition-of-psychenomics-inc-novasite-augments-pipeline-of-cns-drug-candidates-james-hauske-phd-joins-novasite-as-executive-vice-president-drug-discovery/#comments</comments>
		<pubDate>Wed, 15 Jun 2005 21:13:30 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[North America]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2005/06/17/novasite-pharmaceuticals-announces-acquisition-of-psychenomics-inc-novasite-augments-pipeline-of-cns-drug-candidates-james-hauske-phd-joins-novasite-as-executive-vice-president-drug-discovery/</guid>
		<description><![CDATA[SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;June 15, 2005&#8211;Novasite Pharmaceuticals Inc., a company focused on the discovery and development of allosteric modulators of G-protein coupled receptors (GPCRs), today announced that it has acquired PsyCheNomicS, Inc., a drug discovery company focused on diseases of the central nervous system (CNS). Financial terms of the transaction were not disclosed. &#8220;The PsyCheNomicS acquisition [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2005/06/15/novasite-pharmaceuticals-announces-acquisition-of-psychenomics-inc-novasite-augments-pipeline-of-cns-drug-candidates-james-hauske-phd-joins-novasite-as-executive-vice-president-drug-discovery/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Magellan Biosciences buys TekCel</title>
		<link>http://www.bioscreening.net/2005/05/16/magellan-biosciences-buys-tekcel/</link>
		<comments>http://www.bioscreening.net/2005/05/16/magellan-biosciences-buys-tekcel/#comments</comments>
		<pubDate>Mon, 16 May 2005 01:06:26 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Mergers and Acquisitions]]></category>
		<category><![CDATA[North America]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2005/05/18/magellan-biosciences-buys-tekcel/</guid>
		<description><![CDATA[Chelmsfordâ€™s Magellan Biosciences has acquired TekCel, a Hopkinton-based maker of sample-management and assay-automation systems for biomedical research. Terms of the transaction were not disclosed. TekCel employs approximately 35 people, all of whom are expected to remain with the company, according to Magellan. According to Robert J. Rosenthal, president and chief executive officer of Magellan, the [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2005/05/16/magellan-biosciences-buys-tekcel/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Trigen and ProCorde Merge to Create Europe&#8217;s First Broad-based Cardiovascular Biotech Company</title>
		<link>http://www.bioscreening.net/2005/04/11/2/</link>
		<comments>http://www.bioscreening.net/2005/04/11/2/#comments</comments>
		<pubDate>Sun, 10 Apr 2005 20:16:03 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Europe]]></category>
		<category><![CDATA[Mergers and Acquisitions]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2005/05/04/2/</guid>
		<description><![CDATA[Complete pipeline of novel, competitive, clinical-stage products addressing major in-hospital and out-patient thrombosis markets &#8212; Extensive portfolio of pre-clinical and discovery-stage programmes and platforms targeting cardiovascular diseases &#8212; Complementary expertise with resulting competences in discovery, development and commercialisation of small molecules and protein therapeutics &#8212; Blue-chip shareholder base (including 3i and HealthCap) and strong management [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2005/04/11/2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

